DBV Technologies Targets Q3 2026 FDA Submission for Peanut Allergy Patch
Event summary
- DBV Technologies anticipates submitting its BLA for the VIASKIN® Peanut Patch in Q3 2026, following productive FDA engagement.
- The company reported $174.9 million in cash reserves as of June 30, 2026, funding operations into Q3 2027.
- R&D expenses increased to $64.6 million for H1 2026, driven by clinical trial activity and BLA preparation.
- Net loss widened to $98.0 million for H1 2026, reflecting commercial infrastructure build-out ahead of potential launch.
The big picture
DBV Technologies is advancing toward a potential commercial launch of its VIASKIN® Peanut Patch, a non-invasive treatment for peanut allergies. The company's progress comes amid growing awareness of food allergy prevalence and shifting clinical practices toward earlier allergen introduction. DBV's ability to secure FDA approval and execute its commercial strategy will be critical in capturing market share in the $20+ billion global allergy treatment market.
What we're watching
- Regulatory Timeline
- Whether DBV can maintain its Q3 2026 BLA submission timeline and secure FDA approval without additional data requests.
- Commercial Readiness
- The pace at which DBV builds out its U.S. commercial infrastructure ahead of a potential launch.
- Cash Burn Management
- How effectively DBV aligns spending with its revised regulatory timeline to extend its cash runway beyond Q3 2027.
Related topics